h ME1111 is a novel small molecule antifungal agent under development for the topical treatment of onychomycosis. Standardization of the susceptibility testing method for this candidate antifungal is needed. Toward this end, 8 independent laboratories determined the interlaboratory reproducibility of ME1111 susceptibility testing. In addition, we subsequently identified 2 strains as quality control (QC) isolates for the method. In the reproducibility study, 5 blinded clinical strains each of Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum were tested, while the QC study tested 6 blinded T. rubrum or T. mentagrophytes ATCC strains. Testing was performed in frozen microtiter panels according to the Clinical and Laboratory Standards Institute (CLSI) M38-A2 methodology. In the reproducibility study, 9 of 15 clinical strains showed interlaboratory agreement of >90% at the 80% inhibition endpoint, with a range of agreement of 76.2% to 100%. In the QC study, 4 of the 6 ATCC strains showed interlaboratory agreement of >90%. ME1111 demonstrated excellent interlaboratory agreement when tested against dermatophytes. Based on this data, the CLSI Subcommittee on Antifungal Susceptibility Tests approved the susceptibility testing of ME1111 against dermatophytes according to M38-A2 methodology, which stipulates RPMI 1640 as the test medium, an inoculum size of 1 to 3 ؋ 10 3 CFU/ml, and an incubation time and temperature of 96 h at 35°C. The MIC endpoint should be 80% inhibition compared with the growth control. T. rubrum ATCC MYA-4438 and T. mentagrophytes ATCC 28185 were selected as QC isolates, with an acceptable range of 0.12 to 1 g/ml for the two strains.
C
urrently available topical agents for the treatment of onychomycosis have low efficacy, and thus, there is a continued need for the development of new topical antifungals (1, 2) . ME1111 showed potent antifungal activity against Trichophyton rubrum and Trichophyton mentagrophytes (the major etiologic agents of onychomycosis) strains isolated in Japan and reference fungal strains with an MIC range of 0.12 to 0.5 mg/liter and with an MIC 50 and an MIC 90 of 0.5 mg/liter for both (3) . ME1111 is a novel antifungal whose small molecular weight enhances its ability to penetrate the nail plate to reach the nail bed where the infection resides. ME1111 inhibits succinate dehydrogenase (complex II) (4) , and the fungicidal activity of ME1111 seems to be due to its inhibition of this enzyme, which leads to the blockade of ATP production.
The standardized method for the susceptibility testing of dermatophytes was added to the Clinical and Laboratory Standards Institute (CLSI) approved standard M38-A2 following an interlaboratory study involving ciclopirox, fluconazole, griseofulvin, itraconazole, posaconazole, terbinafine, and voriconazole (5). However, this standard does not specifically reference ME1111.
Therefore, in order for ME1111 to be included in this standard, an interlaboratory study was needed to evaluate the reproducibility of the MICs of ME1111 against recent clinical isolates of dermatophytes. Additionally, in accordance with CLSI standard M23-A3, an interlaboratory study was required to identify quality control (QC) strains to monitor the precision and accuracy of the procedure, the performances of the reagents, and the performances of persons who read, interpret, and report the results (6) .
In the reproducibility study, eight independent laboratories tested the in vitro antifungal activity of ME1111 against 15 clinical dermatophyte isolates. Based on these investigations, QC isolates for ME1111 were identified and were subsequently approved by the CLSI Subcommittee on Antifungal Susceptibility Tests. Study design. (i) Reproducibility study. In order to determine the reproducibility of the susceptibility testing of ME1111 against dermatophytes, a study was designed to test identical clinical strains in centrally prepared microtiter plates. The eight participating laboratories were supplied with frozen microtiter plates in three lot numbers of RPMI 1640 (lots M13372A, M13372B, and M13372C) prepared by ThermoFisher (Westlake, OH). These plates were configured with alternating rows containing serial dilutions of ME1111 (Meiji Seika Pharma Co., Ltd., Tokyo, Japan) in a range of 0.004 to 8 g/ml and of ciclopirox (Sigma-Aldrich) in a range of 0.016 to 8 g/ml to accommodate the testing of 4 dermatophyte strains per plate. Ciclopirox was included on the test panels as an internal control for panel production, media quality, and inoculum preparation. Each pair of rows also contained two wells of RPMI 1640 without antifungal agents, which acted as growth and sterility controls. Ten-milliliter tubes of each lot number of RPMI 1640 were also supplied for inoculum preparation.
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(ii) Isolates tested. Isolates were chosen from the culture collection of clinical isolates maintained at the Center for Medical Mycology, Case Western Reserve University, Cleveland, OH. These isolates were originally subcultured onto potato dextrose agar (PDA) slants, incubated at 30°C until luxuriant, and frozen at Ϫ80°C. Stored isolates were thawed and subcultured onto PDA plates, from which sets of new slants were prepared. Each laboratory was sent a set of five blinded pairs of three dermatophyte clinical strains, which included T. rubrum (MRL 28661, 28663, 28669, 28674, and 28675), T. mentagrophytes (MRL 27777, 28313, 28360, 28556, and 28641), and Epidermophyton floccosum (MRL 27435, 27512, 27573, 27580, and 27409). T. rubrum ATCC MYA-4438 and T. mentagrophytes ATCC MYA-4439 were tested as controls.
(iii) Susceptibility method. At each site, isolates were subcultured onto a PDA plate and were incubated at 30°C for 5 to 7 days. Cereal agar was used to grow T. rubrum strains to induce better conidiation. Following incubation, conidia were harvested to sterile water by dislodging them from the agar surface using a sterile swab and were allowed to settle for 5 to 10 min. They were subsequently counted with a hemacytometer and adjusted to twice the concentration needed for testing, 1 to 3 ϫ 10 3 CFU/ml. Using a multichannel pipette, two rows of each microtiter plate (one with ME1111 and one with ciclopirox) prepared with the corresponding RPMI 1640 lot were inoculated with 100 l of the inoculum suspension. All microdilution trays were then incubated at 35°C for 96 h.
For ME1111 and ciclopirox, 80% and 100% growth inhibition compared to that of the growth control (no drug exposure) were recorded on Excel spreadsheets provided to each site. Testing was repeated for a total of 10 days.
Identification of quality control strains. Once the reproducibility of ME1111 dermatophyte susceptibility testing was demonstrated, a separate interlaboratory study was undertaken with these same participants to identify suitable QC isolates. Blinded subcultures of six ATCC strains (T. mentagrophytes ATCC MYA-4439, T. mentagrophytes ATCC 28185, T. mentagrophytes ATCC 28187, T. rubrum ATCC MYA-4438, T. rubrum ATCC 28188, and T. rubrum ATCC 18759) were provided to the participating sites. A separate unblinded set of T. rubrum ATCC MYA-4438 and T. mentagrophytes ATCC MYA-4439 were tested alongside these isolates as controls. ME1111 and ciclopirox were tested against all candidate QC strains as described above. Table 1 displays the interlaboratory agreement of MICs read at 80% and 100% inhibition for ME1111 against clinical strains. As can be seen, 9 of 15 strains showed interlaboratory agreement of Ͼ90% at the 80% inhibition endpoint, with a range of agreement of 76.2% to 100%. Similar to the data recorded at 80% inhibition, 9 of 15 strains showed interlaboratory agreement of Ͼ90% at the 100% inhibition endpoint, with a range of agreement of 65.4% to 100%.
RESULTS
Reproducibility study.
In accordance with CLSI M38-A2 (5), ciclopirox showed interlaboratory agreement of Ͼ90% in 14 of 15 clinical strains at the 80% inhibition endpoint, with a range of agreement of 79.0% to 100% (data not shown).
Identification of quality control strains. Table 2 shows the interlaboratory agreement of MICs against candidate QC strains read at 80% and 100% inhibition for ME1111. As can be seen, 4 of the 6 strains (T. rubrum ATCC MYA-4438, ATCC 28188, and ATCC 18759 and T. mentagrophytes ATCC 28185) showed interlaboratory agreement of Ͼ90% at the 80% inhibition endpoint. In contrast to the data recorded at 80% inhibition, only 2 of the 6 strains (T. rubrum ATCC MYA-4438 and ATCC 28188) showed interlaboratory agreement of Ͼ90% at the 100% inhibition endpoint.
The CLSI dermatophyte reference strains T. rubrum ATCC MYA-4438 and T. mentagrophytes ATCC MYA-4439 were included with each run by each site. At the 80% inhibition endpoint, 99.2% of the MIC values fell within the range of 0.12 to 0.5 g/ml for ME1111 against T. rubrum ATCC MYA-4438, while 100% of the MIC values were within this same range against T. mentagrophytes ATCC MYA-4439. At the 100% inhibition endpoint, 100% of the MIC values fell within the range of 0.25 to 1 g/ml for ME1111 against T. rubrum ATCC MYA-4438 and T. mentagrophytes ATCC MYA-4439.
Blind testing of isolate 4 (T. rubrum ATCC MYA-4438) dem- onstrated 98.3% inclusion within a range of 0.12 to 1 g/ml, and separate testing of T. rubrum ATCC MYA-4438 as daily QC resulted in 99.2% inclusion within a range of 0.12 to 0.5 g/ml.
Blind testing of isolate 2 (T. mentagrophytes ATCC 28185) demonstrated 100% inclusion within a range of 0.12 to 1 g/ml, whereas the CLSI reference strain T. mentagrophytes ATCC MYA-4439 (blinded as isolate 1) resulted in 79.6% inclusion within a range of 0.12 to 0.5 g/ml. Therefore, T. rubrum ATCC MYA-4438 and T. mentagrophytes ATCC 28185 were recommended as QC strains for the testing of ME1111. The acceptable ME1111 MIC range for the two strains was identified as 0.12 to 1 g/ml.
With ciclopirox, all of the strains showed interlaboratory agreement of Ͼ90% at the 80% inhibition endpoint, which is in accordance with the CLSI M38-A2 standard for ciclopirox (data not shown).
DISCUSSION
Several previous multicenter studies have been conducted to establish guidelines for the susceptibility testing of yeasts and filamentous fungi, including dermatophytes (7) (8) (9) (10) (11) . These studies were designed to establish standardized methodology to determine the susceptibility of fungi to different antifungal agents in use at the time. As new antifungals were developed, studies were needed to determine the reproducibility of each agent against large panels of fungal isolates in multiple laboratories and also to determine whether these laboratories were consistently able to identify resistant strains among the test panels.
However, reproducibility does not by itself guarantee the appropriateness of a standard method for testing an antifungal. Correlating years of in vitro data with patient clinical outcomes may show that the methodology must be modified for certain drug/ organism combinations. One case in point is the susceptibility testing of echinocandins against Aspergillus species. It was found that the minimum effective concentration, defined as the lowest concentration with visible morphological changes in growth patterns from filamentous to granular signifying abnormal hyphal growth, correlates better with clinical outcome than with the traditional MIC endpoint for echinocandins against Aspergillus strains (3, 12, 13) .
Therefore, interlaboratory studies of new antifungal agents are critical in order to establish the appropriate methodology for determining the susceptibility of fungal strains.
In this study, we were able to show that the novel agent ME1111 can be reliably tested using the CLSI M38-A2 standard. Furthermore, we identified 2 ATCC strains that were appropriate QC strains to monitor the precision and accuracy of the procedure, the performances of the reagents, and the performances of the persons who read, interpret, and report the results.
In order to be consistent with the CLSI M38-A2 standard, we recommended the following test parameters for the testing of ME1111 against dermatophytes. RPMI 1640 should be the test medium, and the inoculum size should be 1 to 3 ϫ 10 3 CFU/ml. Plates should be incubated at 35°C for 96 h, and the endpoint should be 80% inhibition compared with that of the growth control. These test parameters and selected QC strains have subsequently been approved by the CLSI Subcommittee on Antifungal Susceptibility Tests for inclusion in the next version of CLSI M38. Correlation of in vitro ME1111 susceptibility data with clinical outcomes remains to be established. 
